Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502110569

CPC Scientific H-Phe-Ser-Leu-Leu-Arg-Asn-NH2 (trifluoroacetate salt) 5MG
SDP

Supplier:  CPC Scientific THRO006B

Encompass

This is a negative control peptide containing the reversed sequence of the first two amino acids of the receptor-activating (tethered ligand) peptide SFLLRN-NH2. It shows no detectable affinity for the binding sites. Whereas SFLLRN-NH2 effectively displaces [3H]haTRAP, thrombin receptor-activating peptide, the same peptide with serine and phenylalanine reversed, FSLLRN-NH2, does not.SEQUENCE: H-Phe-Ser-Leu-Leu-Arg-Asn-NH2 (trifluoroacetate salt)ONE-LETTER SEQUENCE: FSLLRN-NH2MOLECULAR FORMULA: C34H57N11O8MOLECULAR WEIGHT: 747.89STORAGE CONDITIONS: -20 5 CCAS REGISTRY NUMBER: [374898-11-0]SYNONYMS: (Phe,Ser)-Thrombin Receptor Activator Peptide 6, (Phe,Ser)-Thrombin Receptor 1 (1-6) (human), (Phe,Ser)-PAR-1 (1-6) (human), (Phe,Ser)-Proteinase Activated Receptor 1 (1-6) (human), FSLLRN, (Phe,Ser)-Coagulation Factor II Receptor (1-6) (human)RESEARCH AREA: Hematology, CardiovascularREFERENCES:Ahn, HS. et al. Mol. Pharmacol. 51, 350 (1997)SKU(s): THRO-006A,

Catalog No. 50-211-0569


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.